



## Spyre Therapeutics to Participate in Upcoming March Investor Conferences

February 25, 2025

WALTHAM, Mass., Feb. 25, 2025 [/PRNewswire/](#) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences:

**Event: TD Cowen 45<sup>th</sup> Annual Healthcare Conference**

**Format:** Fireside chat and 1x1 meetings

**Date/Time:** Tuesday, March 4, 2025 at 3:10pm ET

**Location:** Boston, MA

**Event: Jefferies Biotech on the Beach Summit**

**Format:** 1x1 meetings

**Date:** Tuesday, March 11, 2025

**Location:** Miami, FL

Live audio webcasts and replays of the TD Cowen fireside event will be available on the Spyre investor events website at <https://ir.spyre.com/events-and-presentations>.

**About Spyre Therapeutics**

Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes extended half-life antibodies targeting  $\alpha 4\beta 7$ , TL1A, and IL-23. For more information, visit Spyre's website at [www.spyre.com](http://www.spyre.com).

SOURCE Spyre Therapeutics, Inc.